While imminent changes to Kantar Media’s methodology prompted the company not to calculate half-year ad-spending figures, the company did continue to track companies and therapeutic categories. Glaxo, J&J and Pfizer topped the list of biggest individual spenders in ad journals during the first half of 2019, while marketers of cancer drugs (antineoplastic agents) spent far more than marketers of drugs for other conditions.